Eclipse and GE HealthCare led the $56m Series A round in Nucleus RadioPharma.

Eclipse, a private equity firm, and GE HealthCare, a medical technology company, led the $56m Series A round in Nucleus RadioPharma, a startup designed to manufacture radioisotope cancer treatments, with participation from Echo Global, Fox Chase Cancer Center, Granger Management, Mayo Clinic, Mercy Health and University of Missouri. “Theranostic radiopharmaceuticals are offering promise for millions who currently have limited treatment options. As truly targeted therapies, these drugs are proving not only to be highly effective but also to maintain a superior safety profile. This funding advances the reach and impact of these life-saving agents, allowing for therapies that can be mass-produced, and offers hope to those with few alternatives,” Charles S. Conroy, Nucleus RadioPharma CEO.